1. Scrip
  2. >>Leadership
  3. >>Interviews

Acepodia Plays Dual-Payload Ace To Join Global ADC Race

 
• By Dexter Jie Yan

Acepodia’s dual-payload antibody-drug conjugates can link multiple tumor-killing agents without antibody modification. Apart from a GPC3-targeting candidate, the Taiwan-US biotech is also working on a bispecific antibody ADC with two different payloads, its CEO tells Scrip in an interview.

Two,Darts
Acepodia's dual-payload design is believed likely to overcome malignant tumors’ resistance to single-payload ADCs and thus improve survival benefits including overall survival. (Shutterstock)

Acepodia is emerging as one of the world’s few developers of antibody-drug conjugates (ADCs) preparing to advance into the clinic with a dual payload-fixed design of targeted cancer therapy.

Key Takeaways
  • Acepodia is progressing dual-payload antibody-drug conjugates into the clinic based on its proprietary Antibody-Dual-Drugs Conjugation platform, which aims to improve efficacy over existing single-payload ADCs.

Based out of Taipei, Taiwan and Alameda, CA in the US, the small bioventure is pinning high hopes on its proprietary Antibody-Dual-Drugs Conjugation (AD2C) platform to elevate its still preclinical...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Interviews

Degron Eyes Deals For Novel Molecular Glue Degrader Assets

 
• By Dexter Jie Yan

Pursuing first-in-class molecular glue degraders using undruggable targets could eventually help Degron Therapeutics land sizable asset-based deals, CEO Lily Zou tells Scrip.

MetaVia Sees Obesity Opportunities Despite Challenging US Market

 
• By Jung Won Shin

Despite new challenges related to obesity drug insurance coverage in the US, MetaVia's CEO is confident in the company's novel contender, which unlike rival GLP-1 therapies doesn’t require dose titration.

Quotables: Pharma Leaders On The Month’s Hot Topics

 
• By Anabel Costa-Ferreira

The highlights of recent comments and insights from industry executives on the key issues covered in Scrip.

Roivant Staying ‘Patient’ On Deals, Leaving Investors Waiting

 
• By Jessica Merrill

CEO Matt Gline talked to Scrip in an interview about dealmaking and the road back to commercialization.

More from Leadership

All Over For iTeos But Applause For Plan To Return Cash Fast

 
• By Kevin Grogan

The company has moved quickly to wind down operations after its anti-TIGIT pact with GSK collapsed.

Loss Of Exclusivity Product Launches To Fuel Aurobindo’s FY26 Europe Growth

 
• By Vibha Ravi

Aurobindo is banking on launches of loss of exclusivity products and biosimilars to fuel sales in Europe as it awaits a US announcement on tariffs and predicts high single-digit growth overall during FY26 for now

Roivant Staying ‘Patient’ On Deals, Leaving Investors Waiting

 
• By Jessica Merrill

CEO Matt Gline talked to Scrip in an interview about dealmaking and the road back to commercialization.